NCT05756907View on ClinicalTrials.gov

Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

September 15, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

May 30, 2025

Conditions
Advanced Solid TumorPlatinum-resistant Ovarian Cancer
Interventions
BIOLOGICAL

SON-1010

SON-1010 +/- Atezolizumab

Trial Locations (4)

2148

RECRUITING

Blacktown Mt Druitt Hospital, Blacktown

2640

RECRUITING

The Border Cancer Hospital, Albury

5037

RECRUITING

Ashford Cancer Centre Research, Kurralta Park

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

Sponsors
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Sonnet BioTherapeutics

INDUSTRY

NCT05756907 - Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer | Biotech Hunter | Biotech Hunter